Emerging treatments will play a key role in reducing the problem of obesity, according to research analysts Frost & Sullivan.
Surgical procedures, appetite-suppressing drugs and the use of weight loss devices, such as gastric pacemakers, will all help to reduce the number of clinically-obese patients and their associated health risks.
Many obese patients who have already attempted to lose weight through dieting and exercise are opting for elective surgical procedures to ensure weight loss and provide them with a better quality of life.
Researchers are constantly working to improve surgical techniques in order to develop more efficient and less invasive procedures and the growing use of laparoscopy, or keyhole surgery, means that surgeons are now able to perform a greater number of weight loss surgeries with ease.
Healthcare companies are also researching anti-obesity treatment therapies to help develop innovative treatment procedures and the number of studies of weight loss drugs is growing.
Research analyst Sangeetha Prabakar comments: "Pharmacotherapy [appetite suppressant medication] … is recommended both for obese individuals with a body mass index (BMI) of 30+ who do not have any associated health risks such as type two diabetes, heart disease, hypertension and stroke, in addition to moderately obese patients with two or more collateral conditions."
Ms Prabakar reveals that advances in drug discovery technologies are fuelling interest in the possibilities of therapeutic weight loss drugs.
"As a result, there are several new drugs in the developmental pipeline and the clinical trial stage."
The analyst adds that, despite significant developments in treatment options such as obesity surgery and implantable devices, drug-based approaches will be necessary to address the needs of a "broader market", as surgery is "a solution mainly for the significantly obese patients".